ArticleAnnals of surgical oncology2025
Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Case Report: Spindle cell metaplastic breast carcinoma.Frontiers in oncology · 2026Article
- Case Report: Triple-negative metaplastic breast carcinoma with primary resistance to neoadjuvant chemoimmunotherapy, refractory tumor necrosis-related fever, and rapid postoperative disease progression.Frontiers in oncology · 2026Article
- ASO Author Reflections: Reevaluating Treatment Sequence in Metaplastic Breast Cancer.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetaplastic breast carcinoma (MpBC) is a rare breast cancer subtype frequently exhibiting triple-negative receptor status and poor response to chemotherapy. The optimal treatment sequence for MpBC remains unclear. This study evaluated overall survival (OS) in MpBC patients treated with neoadjuvant chemotherapy (NACT) versus upfront surgery and adjuvant chemotherapy using the National Cancer Database (NCDB).
methodsA retrospective cohort analysis was performed using the NCDB to identify patients with stage I-III MpBC diagnosed from 2010 to 2019 who received either NACT followed by surgery or upfront surgery and adjuvant chemotherapy. Patients with metastatic disease or missing survival data were excluded. Kaplan-Meier and Cox proportional hazards models were used to estimate OS. Primary endpoints included pathologic complete response (pCR), breast conservation rate, and 5-year OS.
resultsOf 5136 patients, 3491 (67.9%) underwent upfront surgery and 1645 (32.1%) received NACT. The 5-year OS was significantly better in patients treated with upfront surgery and adjuvant chemotherapy (hazard ratio [HR] 0.556, 95% confidence interval [CI] 0.464-0.667; p < 0.0001). The pCR rate was 4.92%. Patients receiving NACT had a lower breast conservation rate than those undergoing upfront surgery (33.25% vs. 49.53%; p < 0.0001). Adjuvant chest wall radiation was associated with improved OS (HR 0.641, 95% CI 0.536-0.766, p < 0.0001).
conclusionsNACT was associated with worse OS in MpBC, likely due to its chemotherapy-resistant biology and low pCR rate. For patients with resectable MpBC, upfront surgery and adjuvant chemotherapy and radiation may offer better outcomes. Further research is needed to clarify the role of immunotherapy and advance systemic treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.